Analytical Data
-
Gene name
JAM-A/CD321
- Application
-
Alternative Names
CD321; F11R; KAT; JAM-A; JAMA; JCAM; PAM1; Coagulation Factor XI Receptor; Platelet F11 receptor; Platelet adhesion molecule 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9Y624
-
Expression Region
Phe64~Leu249
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
JAM-A (Junctional Adhesion Molecule A), also known as CD321, is a cell adhesion molecule predominantly expressed in endothelial cells and immune cells. It plays a crucial role in maintaining the integrity of tight junctions in epithelial and endothelial barriers, regulating leukocyte transmigration, and contributing to various physiological and pathological processes, including inflammation, tumor metastasis, and tissue regeneration. The research surrounding JAM-A/CD321 has gained increasing interest due to its involvement in various diseases, such as cancer, autoimmune disorders, and cardiovascular diseases, where it can influence cell signaling and adhesion mechanisms. Additionally, the functional diversity of JAM-A is highlighted by its interactions with multiple binding partners, including integrins and other adhesion molecules, which modulate cell behavior and fate. The development of recombinant JAM-A proteins facilitates detailed studies of its structure-function relationship, underlying molecular mechanisms, and potential therapeutic applications. Understanding the biological roles of JAM-A/CD321 through recombinant protein studies may offer insights into novel therapeutic strategies targeting inflammatory and metastatic pathways, highlighting its significance in biomedical research and potential clinical interventions.
